Trait Information | |
Identifier | OBA_2050200 |
Description | The amount of a prostate-specific antigen when measured in anatomical entity. [AUTO: patterns/patterns/entity_attribute_location] | Trait category |
Other trait
|
Synonym | anatomical entity prostate-specific antigen amount |
Polygenic Score ID & Name | PGS Publication ID (PGP) | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants |
Ancestry distribution GWAS Dev Eval |
Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS003378 (PSA_PGS_128) |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Prostate-specific antigen (PSA) levels | prostate specific antigen amount | 128 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003378/ScoringFiles/PGS003378.txt.gz |
PGS003379 (PSA_PGS_CSx) |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Prostate-specific antigen (PSA) levels | prostate specific antigen amount | 1,071,278 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS003379/ScoringFiles/PGS003379.txt.gz |
PGS005107 (PGS-PSA111) |
PGP000696 | Shi M et al. EBioMedicine (2023) |
Prostate-specific antigen (PSA) levels | prostate specific antigen amount | 111 | - |
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS005107/ScoringFiles/PGS005107.txt.gz |
PGS Performance Metric ID (PPM) |
Evaluated Score |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM016240 | PGS003378 (PSA_PGS_128) |
PSS010066| European Ancestry| 5,725 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.169 | — | Partial R2 (%, variation explained by the PGS only): 7.33 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016241 | PGS003378 (PSA_PGS_128) |
PSS010073| Multi-ancestry (including European)| 25,917 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.207 | — | Partial R2 (%, variation explained by the PGS only): 8.0 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016242 | PGS003378 (PSA_PGS_128) |
PSS010072| European Ancestry| 22,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.213 | — | Partial R2 (%, variation explained by the PGS only): 8.78 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016243 | PGS003378 (PSA_PGS_128) |
PSS010070| African Ancestry| 2,936 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.154 | — | Partial R2 (%, variation explained by the PGS only): 3.36 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016244 | PGS003378 (PSA_PGS_128) |
PSS010068| African Ancestry| 1,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.163 | — | Partial R2 (%, variation explained by the PGS only): 3.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016245 | PGS003378 (PSA_PGS_128) |
PSS010069| African Ancestry| 1,763 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.146 | — | Partial R2 (%, variation explained by the PGS only): 3.32 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016246 | PGS003378 (PSA_PGS_128) |
PSS010071| East Asian Ancestry| 257 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.136 | — | Partial R2 (%, variation explained by the PGS only): 2.45 | Age at PSA measurement, genetic ancestry PC1-PC10 computed within ancestry group | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016239 | PGS003378 (PSA_PGS_128) |
PSS010067| Multi-ancestry (including European)| 5,883 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.168 | — | Partial R2 (%, variation explained by the PGS only): 7.16 | Age at PSA measurement, population-specific genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1 |
PPM016248 | PGS003379 (PSA_PGS_CSx) |
PSS010066| European Ancestry| 5,725 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.194 | — | Partial R2 (%, variation explained by the PGS only): 8.6 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,058,173 SNPs) |
PPM016249 | PGS003379 (PSA_PGS_CSx) |
PSS010073| Multi-ancestry (including European)| 25,917 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.258 | — | Partial R2 (%, variation explained by the PGS only): 9.61 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016250 | PGS003379 (PSA_PGS_CSx) |
PSS010072| European Ancestry| 22,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.283 | — | Partial R2 (%, variation explained by the PGS only): 10.94 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016251 | PGS003379 (PSA_PGS_CSx) |
PSS010070| African Ancestry| 2,936 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.134 | — | Partial R2 (%, variation explained by the PGS only): 3.11 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016252 | PGS003379 (PSA_PGS_CSx) |
PSS010068| African Ancestry| 1,173 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.098 | — | Partial R2 (%, variation explained by the PGS only): 1.64 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016247 | PGS003379 (PSA_PGS_CSx) |
PSS010067| Multi-ancestry (including European)| 5,883 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.186 | — | Partial R2 (%, variation explained by the PGS only): 8.13 | Age at PSA measurement, within-population genetic ancestry PC1-PC10, genetic ancestry proportions (AFR + EAS) | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,058,173 SNPs) |
PPM016253 | PGS003379 (PSA_PGS_CSx) |
PSS010069| African Ancestry| 1,763 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.157 | — | Partial R2 (%, variation explained by the PGS only): 4.22 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM016254 | PGS003379 (PSA_PGS_CSx) |
PSS010071| East Asian Ancestry| 257 individuals |
PGP000412 | Kachuri L et al. Nat Med (2023) |
Reported Trait: Baseline/pre-randomization log(PSA) | β: 0.258 | — | Partial R2 (%, variation explained by the PGS only): 9.22 | Age at PSA measurement, within-population genetic ancestry PC1-PC10 | Beta per SD increase in PGS; PGS converted to standardized z-score with mean=0 and SD=1; SNPs and weights specific for use in this cohort (1,071,278 SNPs) |
PPM022292 | PGS005107 (PGS-PSA111) |
PSS011904| Multi-ancestry (including European)| 3,110 individuals |
PGP000696 | Shi M et al. EBioMedicine (2023) |
Reported Trait: Prostate specific antigen level > 4 ng/mL | HR: 1.22 [1.11, 1.35] | — | — | Age at first PSA measurement, 10 PCs | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS011904 | — | Median = 6.2 years IQR = [3.7, 10.9] years |
3,110 individuals, 100.0 % Male samples |
Median = 56.6 years IQR = [51.4, 61.5] years |
European, African unspecified | — | BioVU | No prostate cancer and prostate specific antigen level < 4 mg/mL at baseline |
PSS010066 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,725 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.998; mean EUR = 0.991 | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010067 | Baseline/pre-randomization PSA in men without prostate cancer | — | 5,883 individuals, 100.0 % Male samples |
— | European, Not reported | Multi-ancestry pooled sample | PCPT | Minimum enrollment age was 55 years with serum PSA <= 3 ng/mL |
PSS010068 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,173 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (Predominantly West African) |
West African (AFR) ancestry cluster based on SNPWEIGHTS score >=0.80; median AFR = 0.855; mean AFR = 0.861 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010069 | Baseline/pre-randomization PSA in men without prostate cancer | — | 1,763 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
0.20 < West African (AFR) ancestry score <0.80 based on SNPWEIGHTS; median AFR = 0.673; mean AFR = 0.602 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010070 | Baseline/pre-randomization PSA in men without prostate cancer | — | 2,936 individuals, 100.0 % Male samples |
— | African American or Afro-Caribbean (West African admixed) |
West African (AFR) ancestry score >0.20 based on SNPWEIGHTS; median AFR = 0.765; mean AFR = 0.705 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010071 | Baseline/pre-randomization PSA in men without prostate cancer | — | 257 individuals, 100.0 % Male samples |
— | East Asian (Predominantly East Asian) |
East Asian (EAS) ancestry cluster based on SNPWEIGHTS score >=0.80; median EAS = 0.978; mean EAS = 0.972 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010072 | Baseline/pre-randomization PSA in men without prostate cancer | — | 22,173 individuals, 100.0 % Male samples |
— | European (Predominantly European) |
European (EUR) ancestry cluster based on SNPWEIGHTS score >=0.80; median EUR = 0.995; mean EUR = 0.986 | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |
PSS010073 | Baseline/pre-randomization PSA in men without prostate cancer | — | 25,917 individuals, 100.0 % Male samples |
— | European, African American or Afro-Caribbean | Multi-ancestry pooled sample | SELECT | Minimum enrollment age was 50 years for African Americans and 55 years for all other men; serum PSA <= 4 ng/mL |